Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.

MLA

Feng, Po-Hao, et al. “Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.” Journal of Thoracic Oncology, vol. 13, no. 7, July 2018, pp. 958–67. EBSCOhost, https://doi.org/10.1016/j.jtho.2018.03.032.

APA

Feng, P.-H., Chen, K.-Y., Huang, Y.-C., Luo, C.-S., Wu, S. M., Chen, T.-T., Lee, C.-N., Yeh, C.-T., Chuang, H.-C., Han, C.-L., Lin, C.-F., Lee, W.-H., Kuo, C.-H., & Lee, K.-Y. (2018). Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 13(7), 958–967. https://doi.org/10.1016/j.jtho.2018.03.032

Chicago

Feng, Po-Hao, Kuan-Yuan Chen, Yu-Chen Huang, Ching-Shan Luo, Shen Ming Wu, Tzu-Tao Chen, Chun-Nin Lee, et al. 2018. “Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.” Journal of Thoracic Oncology 13 (7): 958–67. doi:10.1016/j.jtho.2018.03.032.